BAF complex changes in aggressive B-cell lymphoma
BAF complex deregulation in lymphoma
This project aims to find treatments that target defects in the BAF gene complex for people with aggressive B-cell lymphomas like Burkitt lymphoma and diffuse large B-cell lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11141625 on NIH RePORTER |
What this research studies
From a patient point of view, scientists are trying to understand how common mutations in genes called ARID1A and SMARCA4 break the BAF (SWI/SNF) complex and help lymphomas grow. They will examine patient tumor samples and use laboratory models to see how these changes alter gene activity. The team will test drugs or strategies in cells and animal models that might counteract the defective BAF complex. Findings may point to new, more precise treatments that could be moved into clinical trials later.
Who could benefit from this research
Good fit: People with aggressive B-cell lymphomas, especially Burkitt lymphoma or diffuse large B-cell lymphoma, whose tumors carry mutations in BAF complex genes such as ARID1A or SMARCA4 would be most relevant.
Not a fit: Patients whose tumors do not have BAF complex or ARID1A/SMARCA4 mutations, or people with non-B-cell cancers, are less likely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could lead to targeted therapies that work better and cause fewer side effects than current high-dose chemotherapy for some aggressive B-cell lymphomas.
How similar studies have performed: Targeting chromatin-remodeling complexes is an emerging approach with promising preclinical results, but therapies specifically aimed at BAF complex mutations in these lymphomas remain largely unproven in patients.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Green, Michael Richard — University of Tx Md Anderson Can Ctr
- Study coordinator: Green, Michael Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.